ArticleMedicine2026
Bidirectional causal associations between Sjögren syndrome and gastrointestinal disorders: A two-sample Mendelian randomization study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As a systemic autoimmune disorder, Sjögren syndrome (SS) often has symptoms related to the gastrointestinal manifestations. Nevertheless, the causal relationships between SS and gastrointestinal disorders remain incompletely understood. We implemented bidirectional Mendelian randomization (MR) framework to examine causal links between SS and 7 gastrointestinal diseases, including gastric ulcer (GU), duodenal ulcer (DU), irritable bowel syndrome (IBS), Crohn disease (CD), ulcerative colitis (UC), noninfectious gastroenteritis (NGE), and constipation (CP). The inverse-variance weighted approach served as the primary analytical tool while additional techniques used include MR-Egger, weighted median and weighted mode methods. Sensitivity analyses were carried out to determine if there was any evidence of pleiotropy and heterogeneity. Genetic liability for SS was linked with an increased risk of GU (odds ratio [OR] = 1.055, 95% CI = 1.013-1.100) and a reduced risk of IBS (OR = 0.970, 95% CI = 0.948-0.993). Reverse MR analysis indicated that NGE increases the risk of SS (OR = 1.347, 95% CI = 1.118-1.622). Causative relations were not shown between SS and DU, CD, UC, or CP. Sensitivity testing showed stability of the results. This MR analysis presents genetic evidence suggesting that SS increases the risk of GU and decreases the risk of IBS whereas NGE appears to increase the chance of having SS. No causative links with DU, CD, UC, and CP were discovered. These findings support the stratified gastrointestinal monitoring of SS and emphasize the importance of managing gut inflammatory processes within the context of reducing autoimmune risk. However, the protective effect of SS against IBS needs to be investigated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.